This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-22. Anything still debated is marked as such rather than presented as settled.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
On 2 January 2023, more "revogaços" happened, measures included stopping the privatization process of some eight state-owned companies (such as the Correios and Petrobras) and dismissing almost a thousand appointees in federal posts linked in some way to the Bolsonaro government. On 11 January, Lula signed into law the project which makes the CPF the only necessary document for identification, after its approval by the Federal Congress.
== Reactions == Homoarginine can increase the availability of nitric oxide, and this is the basis of many of its functions. It can serve as a substrate for NO synthase itself. It can also inhibit arginase, an enzyme that competes with NO synthase for arginine. The resulting increase in the intracellular concentration of arginine leads to increased production of NO from it by NO synthase.
Nuclear fuel data and analysis from the U.S. Energy Information Administration World Uranium deposit maps Dittmar, William (1888). "Uranium" . Encyclopædia Britannica. Vol. XXIV (9th ed.). p. 7. Annotated bibliography for uranium from the Alsos Digital Library NLM Hazardous Substances Databank – Uranium, Radioactive CDC – NIOSH Pocket Guide to Chemical Hazards ATSDR Case Studies in Environmental Medicine: Uranium Toxicity Archived 4 February 2016 at the Wayback Machine U.S. Department of Health and Human Services Uranium at The Periodic Table of Videos (University of Nottingham)
Sources: en.wikipedia.org
In October 2011, a Bowery Historic District was registered with the New York State Register of Historic Places and therefore was automatically nominated for listing on the National Register of Historic Places. A grassroots community organization named Bowery Alliance of Neighbors (BAN) in association with the community-based housing organization called the Two Bridges Neighborhood Council led the effort for creation of the historic district. The designation means that property owners will have financial incentives to restore rather than demolish old buildings on the Bowery. BAN was recognized for its preservation efforts with a Village Award from the Greenwich Village Society for Historic Preservation in 2013. The historic district runs from Chatham Square to Astor Place on both sides of the Bowery.
== Secretion and Regulation == Release of little gastrin I is triggered by the presence of proteins and amino acids in the stomach, gastric distension as well as elevated stomach pH. The release is also promoted by vagal nerve stimulation. Secretion is inhibited by Somatostatin and by acidic gastric pH. This forms a negative feedback loop. Its half-life in circulation is short, around 3-7 minutes, after which it is mainly broken down by the kidneys .
== Awards and honours == Beynon received the Sigma Xi Research Award, Purdue University in 1973, the Marice F. Hasler Award in 1979, the Jozef Stefan Medal in 1980, the Medal of the Serbian Chemical Society in 1981, the Techmart Trophy of the British Technology Group in 1984, the Jan Marc Marci Medal, Czechoslovak Spectroscopic Society in 1984, the International Mass Spectrometry Society Thomson Medal in 1985, the American Chemical Society Field and Franklin Award for Outstanding Work in Mass Spectrometry in 1987, the British Mass Spectrometry Society Aston Medal in 1998, and the Italian Mass Spectrometry Society Gold Medal in 1990. He was the Founder chairman British Mass Spectrometry Society (1960), a founding member of the American Society for Mass Spectrometry (1967), and Founder President of the European Mass Spectrometry Society (1993). Beynon was elected to the Royal Society in 1971. He authored over 350 scientific publications. and several books on mass spectrometry. In 1987, Beynon was founding editor-in-chief of the journal Rapid Communications in Mass Spectrometry.
As in the 2023 election, the electoral system followed that of the 2021 amendment of the 2017 constitution. The 500 members of the House of Representatives were elected by parallel voting. 400 seats were elected from single-member constituencies by first-past-the-post voting and 100 seats by proportional representation. Voters cast separate ballots for the two sets of seats. The 100 party-list seats were distributed under the "100 divisor" formula, restored in 2022 after parliament failed to finalise a rival draft within its 180-day deadline. The national party-list vote is divided by 100 to give a quota; each party takes one seat for every whole quota it has won, and the seats still unfilled go to the parties with the largest fractional remainders. List seats are awarded on top of constituency seats rather than in compensation for them, so a party that sweeps the constituencies keeps its full proportional entitlement as well. Writing shortly before the system was first used, Napon Jatusripitak of the ISEAS–Yusof Ishak Institute observed that cutting the number of list seats from 150 to 100 raised the share of the vote needed to win one and allowed larger parties to take a higher proportion of seats than of votes. At the 2026 election the 35,030,579 valid party-list votes produced a quota of 350,306.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.